DFX Intelligence
Venture Capital Intelligence
Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.
Firms / Vida Ventures Management
Vida Ventures Management
Institutional venture firmBoston, MAvidaventures.comSEC venture capital fund adviserpart of Vida Ventures
One of 3 advisers that share vidaventures.com; the firm is Vida Ventures. Vida Ventures Advisors, VV Manager LLC. Each keeps its own CRD, funds and filings; the grouping is the website each swore to on Form ADV and is recomputed every pass.
venture manager, reported GAV $779M across 2 vehicles
Importance
33
moderate
Active deployment
8
low
Emerging
0
low
Completeness
56
elevated
Freshness
99
high
Research priority
9
low
Identity and regulatory footprint
- Headquarters
- Los Angeles, CAadviserinfo.sec.gov
- Office address
- 10100 SANTA MONICA BLVD, SUITE 1500, Los Angeles, CA, 90067adviserinfo.sec.gov
- Business phone
- 818-800-5840adviserinfo.sec.gov
- Website
- https://vidaventures.com/
- SEC adviser type
- exempt reporting adviseradviserinfo.sec.gov
- SEC exemption claimed
- venture capital fund adviseradviserinfo.sec.govItem 2.B(1): advises solely venture capital funds
- Latest Form ADV
- Mar 19, 2026
- Private funds reported
- 2 (2 venture capital funds)adviserinfo.sec.gov
- Private fund gross assets
- $752Madviserinfo.sec.govreported GAV of the funds, the adviser's own number; not fund size, not dry powder
- Owners on Schedule A
- Bellco Capital LLC (Member), E
- business phone
- 415-378-9984adviserinfo.sec.govpublished by the subject
- business phone
- 818-800-5840adviserinfo.sec.govpublished by the subject
Stated thesis versus observed behaviour
8 observed deals
Stated (the firm’s website)
- Sectors
- not stated or not yet read
- Stages
- not stated or not yet read
- Geography
- not stated
- Check size
- not stated; DFX does not estimate checks from round sizes
Observed (from deals on record)
Stage at participation: no observed deals yet
Stage at first entry: no observed deals yet
Sectors
Biotechnology 75%Pharmaceuticals 13%Other Health Care 13%
lead rate n/afollow-on rate n/anew logos, 12 months 2
Funds and vehicles
2 reported
| Vehicle | Type | Vintage | Lifecycle | Reported GAV | Owners | Form D sold | Latest Form D |
|---|---|---|---|---|---|---|---|
| Vida Ventures III, L.P. | Fund | unknown | Unknown | $777M Apr 26, 2024 | 206 | $0 of $750M | Apr 9, 2021 |
| Vida Ventures Iii-A, L.P. | Feeder or parallel | unknown | Unknown | $1.8M Apr 26, 2024 | 13 | unknown | unknown |
GAV is the gross asset value the adviser reported on Form ADV for the vehicle, never the fund’s committed size and never dry powder. Form D sold is the amount sold as of the latest filing, never a final close.
Investment team
7 current, 0 departed
Arie Belldegrun
Managing partnerManaging Member · since Dec 1, 2020
Arjun Goyal
Managing partnerManaging Member · since Sep 1, 2021
Helen Susan Kim
Managing partnerManaging Member · since Sep 1, 2021
Rajul Jain
Managing partnerManaging Member · since Sep 1, 2021
Rebecka Belldegrun
Managing partnerManaging Member · since Jan 1, 2004
Stefan Vitorovic
Managing partnerManaging Member · since Sep 1, 2021
Jean-Philippe Kouakou-Zebouah
Platform and operationsChief Financial Officer And Chief Operating Officer · since Dec 1, 2020
Investments on record
8 edges, 8 companies, 8 partner-attributed
| Company | Round | Role | Partner | Round size | This investor | Date | Source |
|---|---|---|---|---|---|---|---|
| SonoThera, Inc. | board seat | unknown · board | Rajul Jain (strongly supported) | unknown | unknown | Jun 30, 2026 | Inference SEC EDGAR Form D data sets (quarterly) |
| Quanta Therapeutics, Inc. | board seat | unknown · board | Rajul Jain (strongly supported) | unknown | unknown | Jun 24, 2026 | Inference SEC EDGAR Form D data sets (quarterly) |
| Affini-T Therapeutics, Inc. | board seat | unknown · board | Arjun Goyal (strongly supported) | unknown | unknown | Oct 15, 2024 | Inference SEC EDGAR Form D data sets (quarterly) |
| Halda Therapeutics, LLC | board seat | unknown · board | Arjun Goyal (strongly supported) | unknown | unknown | Aug 12, 2024 | Inference SEC EDGAR Form D data sets (quarterly) |
| Third Arc Bio, Inc. | board seat | unknown · board | Arjun Goyal (strongly supported) | unknown | unknown | Aug 1, 2024 | Inference SEC EDGAR Form D data sets (quarterly) |
| Scorpion Therapeutics, Inc. | board seat | unknown · board | Arjun Goyal (strongly supported) | unknown | unknown | Jul 16, 2024 | Inference SEC EDGAR Form D data sets (quarterly) |
| Capstan Therapeutics, Inc. | board seat | unknown · board | Rajul Jain (strongly supported) | unknown | unknown | Mar 20, 2024 | Inference SEC EDGAR Form D data sets (quarterly) |
| LB Pharmaceuticals Inc | board seat | unknown · board | Rajul Jain (strongly supported) | unknown | unknown | Jan 10, 2024 | Inference SEC EDGAR Form D data sets (quarterly) |
“This investor” is the amount disclosed for this investor alone; it is unknown unless a source said it. The round size is the whole round.
Co-investors
13 relationships from shared deals, counted for the whole firm
RA Capital Management, LP 2 shared · recurringVivo Capital, LLC 1 shared · one timeCanaan Partners 1 shared · one timeArch Venture Partners 1 shared · one timeOmega Fund Management, LLC 1 shared · one timeSofinnova Investments, Inc. 1 shared · one timeYK Bioventures 1 shared · one timeMPM Bioimpact 1 shared · one timeLightspeed Venture Partners 1 shared · one timeDroia Ventures 1 shared · one timeForbion 1 shared · one time · they led 1Novartis Venture Fund 1 shared · one time · they led 1Chris Weyrer 1 shared · one time
Limited partners
0 disclosed
No LP commitment on record. An LP edge needs a public disclosure with a quote: a pension report (see Limited partners for the plans read), a fund announcement naming the LP, or a Form ADV owner. The fund page carries the LP’s reported performance.
Timeline
9 dated events
- Sep 15, 2026Vida Ventures Management: MICRO_VC -> INSTITUTIONAL_VC (venture manager, reported GAV $779M across 2 vehicles)Classification changedClassificationInferenceno URL
- Sep 1, 2021Helen Susan Kim joined Schedule A of Vida Ventures Management Co. LLC as Managing Member
- Sep 1, 2021Arjun Goyal joined Schedule A of Vida Ventures Management Co. LLC as Managing Director
- Sep 1, 2021Stefan Vitorovic joined Schedule A of Vida Ventures Management Co. LLC as Managing Member
- Sep 1, 2021Rajul Jain joined Schedule A of Vida Ventures Management Co. LLC as Managing Member
- Jun 14, 2021Vida Ventures III, L.P. first reported on Form ADV by Vida Ventures Management Co. LLC (Venture Capital Fund), GAV $773,138,900Fund first reported on Form ADVFundsFactVida Ventures III, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Jun 14, 2021Vida Ventures Iii-A, L.P. first reported on Form ADV by Vida Ventures Management Co. LLC (Venture Capital Fund), GAV $1,861,100Fund first reported on Form ADVFundsFactVida Ventures Iii-A, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Jun 14, 2021Vida Ventures Management Co. LLC first filed Form ADV (ERA, venture capital fund adviser exemption)First SEC adviser filingOrganizationFactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Jan 1, 2004Rebecka Belldegrun joined Schedule A of Vida Ventures Management as Managing Member
Classification history
- Sep 15, 2026Institutional venture firm (confirmed, 95%, cls-1)venture manager, reported GAV $779M across 2 vehicles
- Sep 12, 2026Micro VC (confirmed, 95%, cls-1)venture manager, reported GAV $1.8M across 1 vehicles
Evidence
33 observations from 2 sources